Back to top

oncology-screening: Archive

Moumi Mondal

With HOLX Stock Near 52-Week High, Should You Buy More or Play Safe?

Hologic's business diversification holds strong potential internationally. Also, its discounted valuation makes it attractive from an investment perspective.

BDXPositive Net Change HOLXNegative Net Change QGENPositive Net Change

Zacks Equity Research

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.

ARCTPositive Net Change STRONegative Net Change FULCNegative Net Change BVSNegative Net Change

Zacks Equity Research

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study

Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.

ARCTPositive Net Change GLPGPositive Net Change FULCNegative Net Change BVSNegative Net Change

Zacks Equity Research

AbbVie (ABBV) Gets Nod in EU for Lymphoma Drug's Expanded Use

AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.

ILMNPositive Net Change ARCTPositive Net Change ABBVPositive Net Change GMABNegative Net Change